FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954039346> ?p ?o ?g. }

• W2954039346 abstract "Introduction: Malignant paraganglioma/pheochromocytoma (MPP) are very rare neuroendocrine tumors with heterogeneous prognostic and no gold-standard treatment. MPP can be associated with germline mutations at SDHB gene which encode for a TCA enzyme, the succinate dehydrogenase that catalyzes the oxidation of succinate to fumarate. When mutated, SDHB losses its function, leading to succinate accumulation by inhibiting 2‐oxoglutarate dependent dioxygenases involved in methylation and angiogenesis. Thus alkylating agents, antiagniogenic and demethylating drugs are potential strategies for MPP patients. Aim: This project aimed to establish preclinical models of SDHB invalidated human cell line and to characterize new therapeutic strategies. Material & Methods: Invalidation of SDHB gene has been performed using the CRISPR-Cas9 technology on a human pheochromocytoma cell line (hPHEO1). Isogenic clones have been characterized at the genetic, cellular, proteic, and enzymatic levels through sequencing, immunohistochemistry, western-blotting and enzymatic assays, respectively. The antiproliferative effects of three drugs (temozolomide, sunitinib, azacytidine) have been explored and half maximal inhibitory concentrations (IC50) have been determined on the parental cell line and the 4 clones using the WST1® assay. Results: Four heterozygote isogenic clones have been obtained with 3 different genetic alterations (deletion-insertion). Expression of Ki67 was increased in the SDHB+/- clones. SDHB expression was partially reduced in clones 1 and 2 and almost totally suppressed in clones 3 and 4. For temozolomide and sunitinib, IC50 were significantly lower in SDHB+/- clones (~140 µM for temozolomide and ~1.4 µM for sunitinib) compared to the parental cell line (~1300 µM for temozolomide and ~6 µM for sunitinib) whereas IC50 were similar for azacytidine (~3.5 µM). No significant difference was observed between clones. Conclusion: In this study we obtained 4 SDHB invalidated isogenic clones from the human hPHEO1 cell line, pretty useful for preclinical evaluations in this rare disease. In agreement with literature clones were more sensitive to temozolomide but also to sunitinib. Metabolomic characterization of hPHEO1 and SDHB+/- clones is currently under investigation at baseline and after IC50 treatment of the 3 therapeutic strategies. Drugs’ combinations will be studied in a further step. Citation Format: Constance Lamy, Julien Hadoux, Sylvere Durand, Abir Alghuzlan, Julie Riviere, Deborah Lefevre, Amaury Bongers, Jean-Yves Scoazec, Eric Baudin, Angelo Paci, Sophie Broutin. Preclinical evaluation of new therapeutic strategies on SDHB invalidated clones from human pheochromocytoma cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2937." @default.
• W2954039346 created "2019-07-12" @default.
• W2954039346 creator A5013335730 @default.
• W2954039346 creator A5018477060 @default.
• W2954039346 creator A5036710320 @default.
• W2954039346 creator A5039540803 @default.
• W2954039346 creator A5042575799 @default.
• W2954039346 creator A5066175305 @default.
• W2954039346 creator A5067116958 @default.
• W2954039346 creator A5069910012 @default.
• W2954039346 creator A5072400207 @default.
• W2954039346 creator A5089333180 @default.
• W2954039346 creator A5090572918 @default.
• W2954039346 date "2019-07-01" @default.
• W2954039346 modified "2023-10-17" @default.
• W2954039346 title "Abstract 2937: Preclinical evaluation of new therapeutic strategies onSDHBinvalidated clones from human pheochromocytoma cells" @default.
• W2954039346 doi "https://doi.org/10.1158/1538-7445.am2019-2937" @default.
• W2954039346 hasPublicationYear "2019" @default.
• W2954039346 type Work @default.
• W2954039346 sameAs 2954039346 @default.
• W2954039346 citedByCount "1" @default.
• W2954039346 countsByYear W29540393462022 @default.
• W2954039346 crossrefType "proceedings-article" @default.
• W2954039346 hasAuthorship W2954039346A5013335730 @default.
• W2954039346 hasAuthorship W2954039346A5018477060 @default.
• W2954039346 hasAuthorship W2954039346A5036710320 @default.
• W2954039346 hasAuthorship W2954039346A5039540803 @default.
• W2954039346 hasAuthorship W2954039346A5042575799 @default.
• W2954039346 hasAuthorship W2954039346A5066175305 @default.
• W2954039346 hasAuthorship W2954039346A5067116958 @default.
• W2954039346 hasAuthorship W2954039346A5069910012 @default.
• W2954039346 hasAuthorship W2954039346A5072400207 @default.
• W2954039346 hasAuthorship W2954039346A5089333180 @default.
• W2954039346 hasAuthorship W2954039346A5090572918 @default.
• W2954039346 hasConcept C104317684 @default.
• W2954039346 hasConcept C121608353 @default.
• W2954039346 hasConcept C134018914 @default.
• W2954039346 hasConcept C13514818 @default.
• W2954039346 hasConcept C142724271 @default.
• W2954039346 hasConcept C150194340 @default.
• W2954039346 hasConcept C153911025 @default.
• W2954039346 hasConcept C181199279 @default.
• W2954039346 hasConcept C190727270 @default.
• W2954039346 hasConcept C2776734335 @default.
• W2954039346 hasConcept C2777389519 @default.
• W2954039346 hasConcept C2778227246 @default.
• W2954039346 hasConcept C2779277951 @default.
• W2954039346 hasConcept C2779490328 @default.
• W2954039346 hasConcept C2779512018 @default.
• W2954039346 hasConcept C2779620337 @default.
• W2954039346 hasConcept C2780744430 @default.
• W2954039346 hasConcept C2781330172 @default.
• W2954039346 hasConcept C501734568 @default.
• W2954039346 hasConcept C502942594 @default.
• W2954039346 hasConcept C54355233 @default.
• W2954039346 hasConcept C55493867 @default.
• W2954039346 hasConcept C71924100 @default.
• W2954039346 hasConcept C86803240 @default.
• W2954039346 hasConcept C98274493 @default.
• W2954039346 hasConceptScore W2954039346C104317684 @default.
• W2954039346 hasConceptScore W2954039346C121608353 @default.
• W2954039346 hasConceptScore W2954039346C134018914 @default.
• W2954039346 hasConceptScore W2954039346C13514818 @default.
• W2954039346 hasConceptScore W2954039346C142724271 @default.
• W2954039346 hasConceptScore W2954039346C150194340 @default.
• W2954039346 hasConceptScore W2954039346C153911025 @default.
• W2954039346 hasConceptScore W2954039346C181199279 @default.
• W2954039346 hasConceptScore W2954039346C190727270 @default.
• W2954039346 hasConceptScore W2954039346C2776734335 @default.
• W2954039346 hasConceptScore W2954039346C2777389519 @default.
• W2954039346 hasConceptScore W2954039346C2778227246 @default.
• W2954039346 hasConceptScore W2954039346C2779277951 @default.
• W2954039346 hasConceptScore W2954039346C2779490328 @default.
• W2954039346 hasConceptScore W2954039346C2779512018 @default.
• W2954039346 hasConceptScore W2954039346C2779620337 @default.
• W2954039346 hasConceptScore W2954039346C2780744430 @default.
• W2954039346 hasConceptScore W2954039346C2781330172 @default.
• W2954039346 hasConceptScore W2954039346C501734568 @default.
• W2954039346 hasConceptScore W2954039346C502942594 @default.
• W2954039346 hasConceptScore W2954039346C54355233 @default.
• W2954039346 hasConceptScore W2954039346C55493867 @default.
• W2954039346 hasConceptScore W2954039346C71924100 @default.
• W2954039346 hasConceptScore W2954039346C86803240 @default.
• W2954039346 hasConceptScore W2954039346C98274493 @default.
• W2954039346 hasLocation W29540393461 @default.
• W2954039346 hasOpenAccess W2954039346 @default.
• W2954039346 hasPrimaryLocation W29540393461 @default.
• W2954039346 hasRelatedWork W1791099702 @default.
• W2954039346 hasRelatedWork W1982613456 @default.
• W2954039346 hasRelatedWork W2019240478 @default.
• W2954039346 hasRelatedWork W2028660659 @default.
• W2954039346 hasRelatedWork W2079480908 @default.
• W2954039346 hasRelatedWork W2314386122 @default.
• W2954039346 hasRelatedWork W2325736294 @default.
• W2954039346 hasRelatedWork W2564168558 @default.
• W2954039346 hasRelatedWork W2747877968 @default.
• W2954039346 hasRelatedWork W2785626971 @default.
• W2954039346 hasRelatedWork W2802539757 @default.
• W2954039346 hasRelatedWork W2806039546 @default.
• W2954039346 hasRelatedWork W2885821357 @default.

• next